Prevalence of breast cancer in the city of Goiânia, Goiás, Brazil, between 1988 and 2002
Keywords:
Breast neoplasms, Epidemiology, Incidence, Prevalence, BrazilAbstract
CONTEXT AND OBJECTIVE: Studieshave shown increased prevalence rates for breast cancer, relating to higher incidence, longer survival and breast cancer prevention programs among populations. The aim here was to analyze the annual prevalence of breast cancer in Goiânia over a 15-year period. DESIGN AND SETTING: This was a cross-sectional study on women with breast cancer diagnosed in Goiânia, Goiás, Brazil, from 1988 to 2002. METHODS: The breast cancer cases were identified in the database of the Population-Based Cancer Registry of Goiânia. The 15-year period was stratified into three five-year periods. The cases were followed up for five years, and the mortality database was used to exclude deaths. The population of the official census was used as the denominator for rate calculations. RESULTS: The coefficient of breast cancer prevalence in Goiania was 22.87/100,000 in 1988 and 220.22/100,000 women in 2002. The analyses for periods showed that in the first period, the rate was 19.39/100,000 and that it was 44.79/100,000 in the last period. For the fifteen years analyzed, the prevalence rate for breast cancer was 127.24/100,000 women. The annual percentage change was 27.07 (P < 0.001; 95% confidence interval, CI: 20.79-33.67) from 1988 to 1992 and 9.39 (P < 0.001; 95% CI: 8.52-10.25) from 1992 to 2002. CONCLUSION: There was an increase in the breast cancer prevalence rate in the city of Goiânia between 1988 and 2002, possibly relating to the improvement in the screening and treatment of breast cancer.
Downloads
References
Pereira MG. Epidemiologia teoria e prática. 4a reimpressão. Rio de Janeiro: Guanabara Koogan; 2000.
Colonna M, Danzon A, Delafosse P, et al. Cancer prevalence in France: time trend, situation in 2002 and extrapolation to 2012. Eur J Cancer. 2008;44(1):115-22.
Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002;97(1):72-81.
Merril RM, Capocaccia R, Feuer EJ, Mariotto A. Cancer prevalence estimatesbasedontumourregistrydatain Surveillance, Epidemiology, and End Results (SEER) Program. Int J Epidemiol. 2000;29(2):197-207.
Micheli A, Mugno E, Krogh V, et al. Cancer prevalence in European registry areas. Ann Oncol. 2002;13(6):840-65.
Forman D, Stockton D, Møller H, et al. Cancer prevalence in the UK: results from the EUROPREVAL study. Ann Oncol. 2003;14(4):648-54.
Lutz JM, Francisci S, Mugno E, et al. Cancer prevalence in Central Europe: the EUROPREVAL Study. Ann Oncol. 2003;14(2):313-22.
Möller T, Anderson H, Aareleid T, et al. Cancer prevalence in Northern Europe: the EUROPREVAL study. Ann Oncol. 2003;14(6):946-57.
International Agency for Research on Cancer. World Health Organization. GLOBOCAN 2008. Cancer Incidence and Mortality Worldwide in 2008. Available from: http://globocan.iarc.fr. Accessed in 2011 (Apr 5).
Martins E, Freitas-Junior R, Curado MP, et al. Evolução temporal dos estádios do câncer de mama ao diagnóstico em um registro de base populacional no Brasil central [Temporal evolution of breast cancer stages in a population-based cancer registry in the Brazilian central region]. Rev Bras Ginecol Obstet. 2009;31(5):219-23.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
Brasil. Ministério da Saúde. Departamento de Informática do SUS. DATASUS. Informações de saúde. Available from: http://tabnet. datasus.gov.br. Accessed in 2011 (Apr 5).
Freitas NMA, Freitas Júnior R, Curado MP, et al. Tendência da incidência e da mortalidade do câncer de mama em Goiânia: análise de 15 anos (1988-2002) [Incidence and mortality trends for breast cancer in Goiânia: analysis of 15 years (1988-2002)]. Rev Bras Mastologia. 2006;16(1):17-21.
Freitas-Junior R, Freitas NM, Curado MP, et al. Variations in breast cancer incidence per decade of life (Goiânia, GO, Brazil): 16-year analysis. Cancer Causes Control. 2008;19(7):681-7.
Moura L, Curado MP, Simões EJ, Cezário AC, Urdaneta M. Avaliação do Registro de Câncer de Base Populacional do Município de Goiânia, Estado de Goiás, Brasil [Evaluation of the Population Based Cancer Registry of the Municipality of Goiânia, Goiás State, Brazil]. Epidemiol Serv Saúde. 2006;15(4):7-17.
National Cancer Institute. Surveillance Research. Cancer Control and Population Sciences. Joinpoint regression program. Available from: http://surveillance.cancer.gov/joinpoint/. Accessed in 2011 (Apr 29)..
Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19(3):335-51.
Brasil. Ministério da Saúde. INCA. Instituto Nacional do Câncer. Programa Nacional de Controle do Câncer de Colo Uterino e da Mama - Viva Mulher. Available from: http://www.inca.gov.br/conteudo_view.asp?id=140. Accessed in 2011 (Apr 5).
Brasil. Ministério do Planejamento, Orçamento e Gestão. IBGE. Instituto Brasileiro de Geografia e Estatística. Acesso a utilização de serviços de saúde - 2003. Available from: http://www.ibge.gov.br/home/estatistica/populacao/trabalhoerendimento/pnad2003/saude/default.shtm. Accessed in 2011 (Apr 11).
Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59(1):27-41.
Milani V, Goldman SM, Finguerman F, et al. Presumed prevalence analysis on suspected and highly suspected breast cancer lesions in São Paulo using BIRADS criteria. Sao Paulo Med J. 2007;125(4):210-4.
Tabár L, Duffy SW, Vitak B, Chen HH, Prevost TC. The natural history of breast carcinoma: what have we learned from screening? Cancer. 1999;86(3):449-62.
Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006;56(3):168-83.
Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer. 2003;39(12):1718-29.
Early Breast Cancer Triallists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-717.
Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 2006;7(12):991-6.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). Breast Cancer. 2008;2.
Available from: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed in 2010 (Oct 25).
Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18(7):1133-44.
Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin. 2004;54(3):150-80.
Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730-56.
Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008;26(12):1948-55.
de Vasconcelos AB, Azevedo e Silva Mendonça G, Sichieri R. Height, weight, weight change and risk of breast cancer in Rio de Janeiro, Brazil. Sao Paulo Med J. 2001;119(2):62-6.
Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-92.
Paulinelli RR, Barbosa MA, Freitas Junior R. Mastectomia profilática– desafios éticos [Prophylactic mastectomy - etical challenges]. Rev Bras Mastologia. 2008;18(1):35-41.
Graves KD, Peshkin BN, Halbert CH, et al. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat. 2007;104(3):321-9.
Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2004;(4):CD002748.
Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-41.
Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast- cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670-4.
Kerlikowske K, Miglioretti DL, Buist DS, et al. Declines in invasive breast cancer and use of postmenopausal hormone therapy in screening mammography population. J Natl Cancer Inst. 2007;99(17):1335-9.
